Does CheckMate 026 Take Bristol Out Of The End Game?
Failure of Bristol's Opdivo in patients with lower expression of PD-L-1 biomarker gives Merck's Keytruda a huge advantage in first-line lung cancer, and leaves market-leading Bristol to wait for combination data.
You may also be interested in...
Merck's Keytruda Enjoys Clean Sweep In Lung Cancer, At Bristol's Expense
Merck came out ahead in the immuno-oncology combination showdown at AACR, with a strong overall survival benefit for Keytruda/chemo in the Phase III KEYNOTE-189 study in first-line NSCLC. The data were seen as practice-changing, but Bristol's CheckMate-227 trial of Opdivo/Yervoy failed to impress in the same way.
J.P. Morgan Notebook Day 2: Bristol Humbled By Competition, Sanofi’s Sarilumab Ready For Review, Justifying Spinraza’s Price And More
Daily round-up of news and notes from the 2017 J.P. Morgan Healthcare conference in San Francisco. Bristol-Myers CEO humbled by PD-1 competition in lung cancer; Sanofi’s sarilumab manufacturing issues resolved; Biogen, Ionis discuss SMA drug’s high cost; Shire happy with Xiidra launch to date; Sarepta says more than 250 patients have started Exondys treatment; J&J’s Gorsky on innovation and pricing; and Amicus reveals US approval strategy for migalastat.